Improved pertussis vaccines based on adjuvants that induce cell-mediated immunity

Expert Review of Vaccines

Volumn 13, Issue 10, 2014, Pages 1253-1264

  Allen, Aideen C ^a   Mills, Kingston H G ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

adjuvant; alum; Bordetella pertussis; cell mediated immunity; pertussis vaccine; Th1 cell; TLR agonist; whooping cough

Indexed keywords

ALUMINUM POTASSIUM SULFATE; BACTERIAL ANTIGEN; PERTUSSIS VACCINE; IMMUNOLOGICAL ADJUVANT;

ADJUVANT THERAPY; ANTIBODY RESPONSE; BACTERIAL CLEARANCE; BACTERIAL IMMUNITY; BORDETELLA PERTUSSIS; CELLULAR IMMUNITY; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; NONHUMAN; PERTUSSIS; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; TH1 CELL; TH17 CELL; ANIMAL; DRUG EFFECTS; IMMUNOLOGY; WHOOPING COUGH;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, BACTERIAL; HUMANS; IMMUNITY, CELLULAR; PERTUSSIS VACCINE; WHOOPING COUGH;

EID: 84905981842     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2014.936391     Document Type: Review

References (104)

1. Black RE, Cousens S, Johnson HL, et al. Global, regional, and. national causes of child mortality in 2008: a systematic analysis. Lancet 2010;375(9730):1969-87
2. Cherry JD. Historical review of pertussis and the classical vaccine. J Infect Dis 1996; 174(Suppl 3):S259-63
3. Mahon BP, Sheahan BJ, Griffin F, et al. Atypical disease after Bordetella pertussis respiratory infection of mice with targeted disruptions of interferon-gamma receptor or immunoglobulin MU chain genes. J Exp Med 1997;186(11):1843-51
4. Byrne P, McGuirk P, Todryk S, Mills KH. Depletion of NK cells results in disseminating lethal infection with Bordetella pertussis associated with a reduction of antigen-specific Th1 and enhancement of Th2, but not Tr1 cells. Eur J Immunol 2004;34(9):2579-88
5. Cohn SE, Knorr KL, Gilligan PH, et al. Pertussis is rare in human immunodeficiency virus disease. Am Rev Respir Dis 1993;147(2):411-13
6. Cantey JB, Sanchez PJ, Tran J, et al. Pertussis: a persistent cause of morbidity and mortality in young infants. J Pediatr 2014;164(6):1489-92
7. Guiso N. Bordetella pertussis and pertussis vaccines. Clin Infect Dis 2009;49(10): 1565-9
8. Gangarosa EJ, Galazka AM, Wolfe CR, et al. Impact of anti-vaccine movements on pertussis control: the untold story. Lancet 1998;351(9099):356-61
9. Higgins SC, Jarnicki AG, Lavelle EC, Mills KH. TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. J Immunol 2006;177(11):7980-9
10. Donnelly S, Loscher CE, Lynch MA, Mills KH. Whole-cell but not acellular pertussis vaccines induce convulsive activity in mice: evidence of a role for toxin-induced interleukin-1beta in a new murine model for analysis of neuronal side effects of vaccination. Infect Immun 2001;69(7): 4217-23
11. Cohen D, Green MS, Katzenelson E, et al. Long-term persistence of anti-diphtheria toxin antibodies among adults in Israel. Implications for vaccine policy. Eur J Epidemiol 1994;10(3):267-70
12. Johnson S. Antibody responses to clostridial infection in humans. Clin Infect Dis 1997; 25(Suppl 2):S173-7
13. Quinello C, Quintilio W, Carneiro-Sampaio M, Palmeira P. Passive acquisition of protective antibodies reactive with Bordetella pertussis in newborns via placental transfer and breast-feeding. Scand J Immunol 2010;72(1):66-73
14. Elahi S, Buchanan RM, Babiuk LA, Gerdts V. Maternal immunity provides protection against pertussis in newborn piglets. Infect Immun 2006;74(5):2619-27
15. Oda M, Cowell JL, Burstyn DG, Manclark CR. Protective activities of the filamentous hemagglutinin and the lymphocytosis-promoting factor of Bordetella pertussis in mice. J Infect Dis 1984;150(6):823-33
16. Trollfors B, Taranger J, Lagergard T, et al. A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl J Med 1995;333(16):1045-50
17. Isacson J, Trollfors B, Taranger J, et al. Safety, immunogenicity and an open, retrospective study of efficacy of a monocomponent pertussis toxoid vaccine in infants. Pediatr Infect Dis J 1994;13(1):22-7
18. Pizza M, Covacci A, Bartoloni A, et al. Mutants of pertussis toxin suitable for vaccine development. Science 1989; 246(4929):497-500
19. van den Berg BM, Beekhuizen H, Willems RJ, et al. Role of Bordetella pertussis virulence factors in adherence to epithelial cell lines derived from the human respiratory tract. Infect Immun 1999;67(3): 1056-62
20. Tuomanen E, Weiss A. Characterization of two adhesins of Bordetella pertussis for human ciliated respiratory-epithelial cells. J Infect Dis 1985;152(1):118-25
21. Urisu A, Cowell JL, Manclark CR. Filamentous hemagglutinin has a major role in mediating adherence of Bordetella pertussis to human WiDr cells. Infect Immun 1986;52(3):695-701
22. Sato H, Sato Y. Bordetella pertussis infection in mice: correlation of specific antibodies against two antigens, pertussis toxin, and filamentous hemagglutinin with mouse protectivity in an intracerebral or aerosol challenge system. Infect Immun 1984;46(2):415-21
23. Kimura A, Mountzouros KT, Relman DA, et al. Bordetella pertussis filamentous hemagglutinin: evaluation as a protective antigen and colonization factor in a mouse respiratory infection model. Infect Immun 1990;58(1):7-16
24. Shahin RD, Brennan MJ, Li ZM, et al. Characterization of the protective capacity and immunogenicity of the 69-kD outer membrane protein of Bordetella pertussis. J Exp Med 1990;171(1):63-73
25. Podda A, Carapella De Luca E, Titone L, et al. Immunogenicity of an acellular pertussis vaccine composed of genetically inactivated pertussis toxin combined with filamentous hemagglutinin and pertactin in infants and children. J Pediatr 1993;123(1): 81-4
26. Rodriguez ME, Hellwig SM, Perez Vidakovics ML, et al. Bordetella pertussis attachment to respiratory epithelial cells can be impaired by fimbriae-specific antibodies. FEMS Immunol Med Microbiol 2006;46(1):39-47
27. Hallander H, Advani A, Alexander F, et al. Antibody Responses to Bordetella pertussis Fim2 or Fim3 following Immunization with a Whole-Cell, Two-Component, or Five-Component Acellular Pertussis Vaccine and following Pertussis Disease in Children in Sweden in 1997 and 2007. Clin Vaccine Immunol 2014;21(2):165-73
28. Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N Engl J Med 1996;334(6):341-8
29. Gustafsson L, Hallander HO, Olin P, et al. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996;334(6):349-55
30. Simondon F, Preziosi MP, Yam A, et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 1997; 15(15):1606-12
31. Pichichero ME, Deloria MA, Rennels MB, et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics 1997;100(5):772-88
32. Guiso N, Njamkepo E, Vie le Sage F, et al. Long-term humoral and cell-mediated immunity after acellular pertussis vaccination compares favourably with whole-cell vaccines 6 years after booster vaccination in the second year of life. Vaccine 2007;25(8):1390-7
33. Plotkin SA. The effectiveness of whole-cell pertussis vaccines. Dev Biol Stand 1997;89: 171-4
34. Edwards KM, Meade BD, Decker MD, et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics 1995;96(3 Pt 2):548-57
35. Friedman RL, Nordensson K, Wilson L, et al. Uptake and intracellular survival of Bordetella pertussis in human macrophages. Infect Immun 1992;60(11):4578-85
36. Lamberti YA, Hayes JA, Perez Vidakovics ML, et al. Intracellular trafficking of Bordetella pertussis in human macrophages. Infect Immun 2010;78(3): 907-13
37. Hellwig SM, Hazenbos WL, van de Winkel JG, Mooi FR. Evidence for an intracellular niche for Bordetella pertussis in broncho-alveolar lavage cells of mice. FEMS Immunol Med Microbiol 1999; 26(3-4):203-7
38. Cheers C, Gray DF. Macrophage behaviour during the complaisant phase of murine pertussis. Immunology 1969;17(6): 875-87
39. Mills KH, Barnard A, Watkins J, Redhead K. Cell-mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model. Infect Immun 1993;61(2): 399-410
40. Mills KH, Ryan M, Ryan E, Mahon BP. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect Immun 1998;66(2):594-602
41. Redhead K, Watkins J, Barnard A, Mills KH. Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity. Infect Immun 1993;61(8):3190-8
42. Leef M, Elkins KL, Barbic J, Shahin RD. Protective immunity to Bordetella pertussis requires both B cells and CD4(+) T cells for key functions other than specific antibody production. J Exp Med 2000;191(11): 1841-52
43. Mahon BP, Brady MT, Mills KH. Protection against Bordetella pertussis in mice in the absence of detectable circulating antibody: implications for long-term immunity in children. J Infect Dis 2000; 181(6):2087-91
44. Barbic J, Leef MF, Burns DL, Shahin RD. Role of gamma interferon in natural clearance of Bordetella pertussis infection. Infect Immun 1997;65(12):4904-8
45. Ryan M, Murphy G, Gothefors L, et al. Bordetella pertussis respiratory infection in children is associated with preferential activation of type 1 T helper cells. J Infect Dis 1997;175(5):1246-50
46. Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005; 24(5 Suppl):S58-61
47. Canthaboo C, Williams L, Xing DK, Corbel MJ. Investigation of cellular and humoral immune responses to whole cell and acellular pertussis vaccines. Vaccine 2000;19(6):637-43
48. Xing DK, Canthaboo C, Corbel MJ. Nitric oxide induction in murine macrophages and spleen cells by whole-cell Bordetella pertussis vaccine. Vaccine 1998;16(1): 16-23
49. Ausiello CM, Lande R, Urbani F, et al. Cell-mediated immune responses in four-year-old children after primary immunization with acellular pertussis vaccines. Infect Immun 1999;67(8):4064-71
50. Ryan M, Murphy G, Ryan E, et al. Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children. Immunology 1998;93(1):1-10
51. Ross PJ, Sutton CE, Higgins S, et al. Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine. PLoS Pathog 2013;9(4):e1003264
52. Andreasen C, Powell DA, Carbonetti NH. Pertussis toxin stimulates IL-17 production in response to Bordetella pertussis infection in mice. PLoS One 2009;4(9):e7079
53. Kolls JK, Khader SA. The role of Th17 cytokines in primary mucosal immunity. Cytokine Growth Factor Rev 2010;21(6):443-8
54. Lenz DH, Weingart CL, Weiss AA. Phagocytosed Bordetella pertussis fails to survive in human neutrophils. Infect Immun 2000;68(2):956-9
55. Warfel JM, Merkel TJ. Bordetella pertussis infection induces a mucosal IL-17 response and long-lived Th17 and Th1 immune memory cells in nonhuman primates. Mucosal Immunol 2013;6(4):787-96
56. van den Berg BM, Beekhuizen H, Mooi FR, van Furth R. Role of antibodies against Bordetella pertussis virulence factors in adherence of Bordetella pertussis and Bordetella parapertussis to human bronchial epithelial cells. Infect Immun 1999;67(3): 1050-5
57. Barnard A, Mahon BP, Watkins J, et al. Th1/Th2 cell dichotomy in acquired immunity to Bordetella pertussis: variables in the in vivo priming and in vitro cytokine detection techniques affect the classification of T-cell subsets as Th1, Th2 or Th0. Immunology 1996;87(3):372-80
58. Winter K, Harriman K, Zipprich J, et al. California pertussis epidemic, 2010. J Pediatr 2012;161(6):1091-6
59. Cherry JD. Epidemic pertussis in 2012 - the resurgence of a vaccine-preventable disease. N Engl J Med 2012;367(9):785-7
60. Octavia S, Sintchenko V, Gilbert GL, et al. Newly emerging clones of Bordetella pertussis carrying prn2 and ptxP3 alleles implicated in Australian pertussis epidemic in 2008-2010. J Infect Dis 2012;205(8): 1220-4
61. de Melker HE, Conyn-van Spaendonck MA, Rumke HC, et al. Pertussis in The Netherlands: an outbreak despite high levels of immunization with whole-cell vaccine. Emerg Infect Dis 1997;3(2):175-8
62. Barret AS, Ryan A, Breslin A, et al. Pertussis outbreak in northwest Ireland, January - June 2010. Euro Surveill 2010; 15:35
63. Amirthalingam G, Gupta S, Campbell H. Pertussis immunisation and control in England and Wales, 1957 to 2012: a historical review. Euro Surveill 2013;18:38
64. Mooi FR, van Oirschot H, Heuvelman K, et al. Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect Immun 1998;66(2):670-5
65. Cherry JD, Gornbein J, Heininger U, Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998;16(20):1901-6
66. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998;16(20):1907-16
67. Taranger J, Trollfors B, Lagergard T, et al. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J Infect Dis 2000;181(3):1010-13
68. Mooi FR, He Q, van Oirschot H, Mertsola J. Variation in the Bordetella pertussis virulence factors pertussis toxin and pertactin in vaccine strains and clinical isolates in Finland. Infect Immun 1999; 67(6):3133-4
69. Packard ER, Parton R, Coote JG, Fry NK. Sequence variation and conservation in virulence-related genes of Bordetella pertussis isolates from the UK. J Med Microbiol 2004;53(Pt 5):355-65
70. Cassiday P, Sanden G, Heuvelman K, et al. Polymorphism in Bordetella pertussis pertactin and pertussis toxin virulence factors in the United States, 1935-1999. J Infect Dis 2000;182(5):1402-8
71. Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl Acad Sci USA 2014;111(2): 787-92
72. Klein NP, Bartlett J, Rowhani-Rahbar A, et al. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med 2012;367(11): 1012-19
73. Bomford R. Will adjuvants be needed for vaccines of the future? Dev Biol Stand 1998;92:13-17
74. Johnson AG, Gaines S, Landy M. Studies on the O antigen of Salmonella typhosa. V. Enhancement of antibody response to protein antigens by the purified lipopolysaccharide. J Exp Med 1956;103(2): 225-46
75. Denoel P, Poolman J, Carletti G, Veitch K. Effects of adsorption of acellular pertussis antigens onto different aluminium salts on the protective activity in an intranasal murine model of Bordetella pertussis infection. Vaccine 2002;20(19-20):2551-5
76. Ghimire TR, Benson RA, Garside P, Brewer JM. Alum increases antigen uptake, reduces antigen degradation and sustains antigen presentation by DCs in vitro. Immunol Lett 2012;147(1-2):55-62
77. Eisenbarth SC, Colegio OR, O'Connor W, et al. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008;453(7198):1122-6
78. Kool M, Petrilli V, De Smedt T, et al. Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J Immunol 2008;181(6):3755-9
79. Asokanathan C, Corbel M, Xing D. A CpG-containing oligodeoxynucleotide adjuvant for acellular pertussis vaccine improves the protective response against Bordetella pertussis. Hum Vaccin Immunother 2013;9:2
80. Atkins H, Davies BR, Kirby JA, Kelly JD. Polarisation of a T-helper cell immune response by activation of dendritic cells with CpG-containing oligonucleotides: a potential therapeutic regime for bladder cancer immunotherapy. Br J Cancer 2003; 89(12):2312-19
81. Kindrachuk J, Jenssen H, Elliott M, et al. A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity. Vaccine 2009;27(34): 4662-71
82. Dias WO, van der Ark AA, Sakauchi MA, et al. An improved whole cell pertussis vaccine with reduced content of endotoxin. Hum Vaccin Immunother 2013;9:2
83. Persing DH, Coler RN, Lacy MJ, et al. Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol 2002;10(10 Suppl):S32-7
84. Boland G, Beran J, Lievens M, et al. Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04. Vaccine 2004;23(3):316-20
85. Geurtsen J, Banus HA, Gremmer ER, et al. Lipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice. Clin Vaccine Immunol 2007;14(7):821-9
86. Hennessy EJ, Parker AE, O'Neill LA. Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov 2010; 9(4):293-307
87. Ryan EJ, McNeela E, Murphy GA, et al. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells. Infect Immun 1999;67(12): 6270-80
88. Lewis DJ, Huo Z, Barnett S, et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One 2009;4(9):e6999
89. Feunou PF, Kammoun H, Debrie AS, et al. Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1. Vaccine 2010;28(43):7047-53
90. Thorstensson R, Trollfors B, Al-Tawil N, et al. A phase I clinical study of a live attenuated Bordetella pertussis vaccine - BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers. PLoS ONE 2014;9(1): e83449
91. Mahon BP, Ryan MS, Griffin F, Mills KH. Interleukin-12 is produced by macrophages in response to live or killed Bordetella pertussis and enhances the efficacy of an acellular pertussis vaccine by promoting induction of Th1 cells. Infect Immun 1996; 64(12):5295-301
92. Garlapati S, Eng NF, Kiros TG, et al. Immunization with PCEP microparticles containing pertussis toxoid, CpG ODN and a synthetic innate defense regulator peptide induces protective immunity against pertussis. Vaccine 2011;29(38):6540-8
93. Hormozi K, Parton R, Coote J. Adjuvant and protective properties of native and recombinant Bordetella pertussis adenylate cyclase toxin preparations in mice. FEMS Immunol Med Microbiol 1999;23(4): 273-82
94. Marr N, Oliver DC, Laurent V, et al. Protective activity of the Bordetella pertussis BrkA autotransporter in the murine lung colonization model. Vaccine 2008;26(34): 4306-11
95. Rennels MB, Deloria MA, Pichichero ME, et al. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines. Pediatrics 2000;105(1):e12
96. PrabhuDas M, Adkins B, Gans H, et al. Challenges in infant immunity: implications for responses to infection and vaccines. Nat Immunol 2011;12(3): 189-94
97. Walsh KP, Mills KH. Dendritic cells and other innate determinants of T helper cell polarisation. Trends Immunol 2013;34(11): 521-30
98. Servier. Available from: www.servier.com/Powerpoint-image-bank
99. Brereton CF, Sutton CE, Ross PJ, et al. Escherichia coli heat-labile enterotoxin promotes protective Th17 responses against infection by driving innate IL-1 and IL-23 production. J Immunol 2011;186(10): 5896-906
100. Conway MA, Madrigal-Estebas L, McClean S, et al. Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells. Vaccine 2001;19(15-16):1940-50
101. Orr B, Douce G, Baillie S, et al. Adjuvant effects of adenylate cyclase toxin of Bordetella pertussis after intranasal immunisation of mice. Vaccine 2007;25(1): 64-71
102. Isaka M, Yasuda Y, Taniguchi T, et al. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant. Vaccine 2003;21(11-12): 1165-73
103. Shim DH, Ko HJ, Volker G, et al. Efficacy of poly[di(sodium carboxylatophenoxy) phosphazene] (PCPP) as mucosal adjuvant to induce protective immunity against respiratory pathogens. Vaccine 2010;28(11): 2311-17
104. Feunou PF, Bertout J, Locht C. T- and B-cell-mediated protection induced by novel, live attenuated pertussis vaccine in mice. Cross protection against parapertussis. PLoS One 2010;5(4):e10178